BioCryst Pharmaceuticals (BCRX) stock surged 5.21% in pre-market trading on Monday, driven by the company's strong full-year 2025 revenue outlook and positive results from a pediatric trial for its flagship drug ORLADEYO.

The biotechnology company raised its full-year 2025 guidance for global net ORLADEYO revenue to between $535 million and $550 million, up from its previous forecast of $515 million to $535 million. This led to an increase in BioCryst's total revenue outlook for 2025 to between $560 million and $575 million, compared to the earlier range of $540 million to $560 million.

The upward revision in guidance was driven by strong patient demand for ORLADEYO in the early part of 2025, as well as indications that more Medicare patients are able to afford the therapy due to lower co-payments under the Inflation Reduction Act. ORLADEYO is an oral, once-daily treatment for the prevention of hereditary angioedema (HAE) attacks in adult and pediatric patients.